Table 3.
Progression-Free survival and overall survival rates of the included patients and association with expression of the studied markers
| Marker | Histopathological subtype | Progression-Free Survival Analysis | Overall Survival Analysis | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| N of Events | Censored | PFS Rate% | P | N of Events | Censored | OS Rate% | P | |||||
| N | Percent | N | Percent | |||||||||
| CLCA2 | Squamous (N=30) | Negative (N=5) | 0 | 5 | 100.0% | 100% | 0.038 | 0 | 5 | 100.0% | 100% | 0.019 |
| Positive (N=25) | 14 | 11 | 44.0% | 42.0% | 16 | 9 | 36.0% | 31.5% | ||||
| Adenocarcinoma (N=30) | Negative (N=29) | 7 | 22 | 75.9% | 74.5% | 0.586 | 13 | 16 | 55.2% | 54.6% | 0.439 | |
| Positive (N=1) | 0 | 1 | 100.0% | 100% | 0 | 1 | 100.0% | 100% | ||||
| SPATS2 | Squamous (N=30) | Negative (N=3) | 0 | 3 | 100.0% | 100% | 0.128 | 0 | 3 | 100.0% | 100% | 0.09 |
| Positive (N=27) | 14 | 13 | 48.1% | 46.6% | 16 | 11 | 40.7% | 37.4% | ||||
| Adenocarcinoma (N=30) | Negative (N=29) | 7 | 22 | 75.9% | 74.5% | 0.586 | 13 | 16 | 55.2% | 54.6% | 0.439 | |
| Positive (N=1) | 0 | 1 | 100.0% | 100% | 0 | 1 | 100.0% | 100% | ||||
| Adipophilin | Squamous (N=30) | Negative (N=27) | 14 | 13 | 48.1% | 46.6% | 0.128 | 16 | 11 | 40.7% | 37.4% | 0.09 |
| Positive (N=3) | 0 | 3 | 100.0% | 100% | 0 | 3 | 100.0% | 100% | ||||
| Adenocarcinoma (N=30) | Negative (N=3) | 0 | 3 | 100.0% | 100% | 0.325 | 0 | 3 | 100.0% | 100% | 0.16 | |
| Positive (N=27) | 7 | 20 | 74.1% | 72.4% | 13 | 14 | 51.9% | 51.2% | ||||
| ST6GALNAC1 | Squamous (N=30) | Negative (N=28) | 14 | 14 | 50.0% | 48.6% | 0.226 | 16 | 12 | 42.9% | 40.0% | 0.18 |
| Positive (N=2) | 0 | 2 | 100.0% | 100% | 0 | 2 | 100.0% | 100% | ||||
| Adenocarcinoma (N=30) | Negative (N=1) | 0 | 1 | 100.0% | 100% | 0.586 | 0 | 1 | 100.0% | 100% | 0.439 | |
| Positive (N=29) | 7 | 22 | 75.9% | 74.5% | 13 | 16 | 55.2% | 54.6% | ||||